All In Biotech

Drug Trial Radar · NCT07870889

Vortosiran in Atrial Fibrillation

A Randomised Active-controlled Trial to Assess the Safety and Pharmacodynamics of Two Blinded Doses of Vortosiran and Open-label Apixaban in Patients With Non-valvular Atrial Fibrillation (AF)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Jul 31, 2028

Study completion Aug 31, 2028

Sponsor

Lead sponsor
Ribocure Pharmaceuticals ABIndustry
Sponsor type
Industry
Collaborators
Link Medical Research AB
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, actively controlled Phase IIb trial to evaluate the safety and pharmacodynamics (PD) of two blinded doses of subcutaneously administered vortosiran and open-label apixaban in patients with AF. The trial consists of three groups including 50 participants each. The participants will be randomized to either the low dose group or the high dose group receiving vortosiran or to the group receiving apixaban. The treatment will be open-label for vortosiran vs apixaban. The vortosiran dose will be blinded to patients and investigators. Both the low- and the high-dose group will receive two doses of vortosiran, the first dose at Day X and the second at Day Y. After 24 weeks, at the end of the vortosiran treatment period, the participants will start an open-label part of the trial and will be switched to standard-of-care apixaban treatment until Week 64 (End of Trial; EOT). Participants in the open-label apixaban arm will receive apixaban as standard of care during the entire trial.

Conditions

  • Non-valvular Atrial Fibrillation (AF)

Interventions

  • VortosiranDrug

    Vortosiran, active drug

  • VortosiranDrug

    Vortosiran, active drug

  • ApixabanDrug

    Comparator, active drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary objectiveTime frame: At week 16
  2. Primary endpointTime frame: At week 16

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Frederiksberg Hospital

    Frederiksberg, Denmark

  • Herlev-Gentofte

    Herlev, Denmark

  • Sykehuset Østfold Kalnes Kardiologisk

    Grålum, Norway

  • Akershus Universitetssykehus Ahus Kardiologisk

    Lørenskog, Norway

  • EMC Silesia spółka z ograniczoną odpowiedzialnością

    Katowice, Poland

  • Centrum Medyczne Vitamedicum

    Krakow, Poland

  • Balsam Medica Sp z o.o.

    Raszyn, Poland

  • Aidport Clinical Trial Hospital

    Skorzewo, Poland

  • Centrum Medyczne LUX MED

    Warsaw, Poland

  • Centrum Badań Klinicznych

    Wroclaw, Poland

  • Centrum Medyczne Oporów

    Wroclaw, Poland

  • Pracownia Badan Klinicznych Salus

    Wroclaw, Poland

  • Danderyds Sjukhus - Hjärtmottagningen

    Danderyd, Sweden

  • SUS Lund, Department of Cardiology

    Lund, Sweden

  • Södersjukhuset, Department of Cardiology

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.